Skip to main content
Laekna, Inc. logo

Laekna, Inc. — Investor Relations & Filings

Ticker · 2105 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 130 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2105

About Laekna, Inc.

http://www.laekna.com

Laekna, Inc. is a science-driven, clinical-stage biotechnology company founded in 2016. The company specializes in the discovery, development, and commercialization of innovative therapies, particularly focusing on immunology treatments. Laekna's core mission is to bring novel therapeutics to patients suffering from cancer (oncology), metabolic diseases, and liver fibrosis, addressing significant unmet medical needs across these therapeutic areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT SUBMISSION OF IND AMENDMENT TO U.S. FDA FOR LAE102 FOR THE TREATMENT OF OBESITY
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement filed on the HKEX about the submission of an IND amendment to the U.S. FDA for a drug candidate; it provides a business update rather than financial results, board changes, or regulatory approvals of share transactions. It does not fit any specialized category (e.g., earnings release, management change, M&A, etc.), so it falls into the catch-all Regulatory Filings category (RNS).
2025-03-31 English
VOLUNTARY ANNOUNCEMENT FIRST VISIT FOR THE FIRST SUBJECT COMPLETED IN PHASE I MULTIPLE ASCENDING DOSE STUDY OF LAE102 FOR THE TREATMENT OF OBESITY
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement updating shareholders on the completion of a Phase I study milestone for a drug candidate. It does not report financial results, governance changes, capital transactions, or dividends, nor is it a request for votes or an investor presentation. It is a general business update that does not fit any specialized category, so it falls under the fallback “Regulatory Filings” category (RNS).
2025-03-26 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Earnings Release Classification · 1% confidence The document is titled “Annual Results Announcement for the year ended December 31, 2024” and contains key business highlights and summarized consolidated financial statements (profit or loss, comprehensive income, balance sheet, cash flow) for that period. It is a preliminary annual earnings announcement rather than the full annual report or other regulatory filing, fitting the definition of an Earnings Release. FY 2024
2025-03-24 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange announcement notifying investors of the date of a forthcoming board meeting to consider and approve the company’s annual results. It is not the annual report itself, nor a management change, dividend notice, or earnings release—it simply schedules a board meeting. There is no attached report or detailed financial data. This type of short corporate announcement falls into the general “Regulatory Filings” category (RNS).
2025-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
Share Issue/Capital Change Classification · 1% confidence The document is the FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed with HKEX, detailing movements in authorised, issued and treasury shares, share option schemes, awards and capital changes for the month. It is not a financial performance report but a regulatory announcement of share capital changes, fitting the Share Issue/Capital Change category.
2025-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
Regulatory Filings Classification · 1% confidence The document is a statutory monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing movements in authorized/issued share capital, share options and other share arrangements. This is a routine regulatory compliance filing rather than an earnings release, report publication announcement, or investor presentation. It does not announce a one‐time capital change event but provides periodic disclosures as required by HKEX. No other specific category applies, so it falls under the generic “Regulatory Filings” category.
2025-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.